Health
Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant sc vs iv trastuzumab – MD Linx
MDLinx original journal summary on Breast Cancer, Oncology from The Breast
Researchers investigated cardiotoxicity related to subcutaneous (s.c.) vs intravenous (i.v.) trastuzumab treatment of early-stage, HER2-positive breast cancer in a real-world population as well as tried to define its predisposing factors. Data for 363 adult patients managed with adjuvant trastuzumab for HER2-positive breast cancer were analyzed retrospectively. It was found that i.v. administration conferred a higher cardiotoxicity rate vs s.c. formulation, and especially in cases with cardiovascular…
-
Noosa News24 hours agoBrisbane man, 39, dies after stabbing at inner city home in early morning attack, prompting investigation
-
General24 hours agoTwo British MPs refused entry into Israel, UK foreign ministry says
-
Business8 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
General18 hours agoTribute unveiled for SA Police Brevet Sergeant Jason Doig after fatal 2023 shooting